Vutrisiran, a new drug made by Alnylam Pharmaceuticals to treat ATTR amyloidosis with cardiomyopathy, reduced the risk of death by 36% in patients, the drugmaker announced June 24.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
